217 related articles for article (PubMed ID: 21159253)
1. [PI3K/Akt/mTOR signaling pathway and non-small cell lung cancer].
QI H; FAN L
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1149-54. PubMed ID: 21159253
[TBL] [Abstract][Full Text] [Related]
2. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway.
Li F; Gu F; Li Q; Zhai C; Gong R; Zhu X
J Biochem Mol Toxicol; 2021 May; 35(5):e22726. PubMed ID: 33491326
[TBL] [Abstract][Full Text] [Related]
3. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
4. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin-1 in lung cancer.
Jian M; Yunjia Z; Zhiying D; Yanduo J; Guocheng J
Mol Carcinog; 2019 Mar; 58(3):358-365. PubMed ID: 30362635
[TBL] [Abstract][Full Text] [Related]
6. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
7. Ganoderic acid DM induces autophagic apoptosis in non-small cell lung cancer cells by inhibiting the PI3K/Akt/mTOR activity.
Xia J; Dai L; Wang L; Zhu J
Chem Biol Interact; 2020 Jan; 316():108932. PubMed ID: 31874162
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway.
Lv X; Li CY; Han P; Xu XY
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2321-2327. PubMed ID: 29762835
[TBL] [Abstract][Full Text] [Related]
9. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
10. Ethyl 2,2-difluoro-2-(2-oxo-2H-chromen-3-yl) acetate attenuates the malignant biological behaviors of non-small cell lung cancer via suppressing EGFR/PI3K/AKT/mTOR signaling pathway.
Zou L; Li X; Lin J; Fang X; Lin J; Zhang L; Zhang Y; Liang Y; Ren J; Liu Y; Huang Z
J Pharm Pharmacol; 2024 Mar; 76(3):269-282. PubMed ID: 38241189
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
12. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Zhao L; Zhang J; Fan Y; Li Y
Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
[TBL] [Abstract][Full Text] [Related]
14. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.
Chen K; Shang Z; Dai AL; Dai PL
Life Sci; 2020 Aug; 255():117816. PubMed ID: 32454155
[TBL] [Abstract][Full Text] [Related]
15. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
17. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway.
Zhu Q; Liang X; Dai J; Guan X
Int J Clin Exp Pathol; 2015; 8(8):9175-81. PubMed ID: 26464663
[TBL] [Abstract][Full Text] [Related]
19. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
20. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
